Place Ursodeoxycholic Acid in Modern Hepatology

Abstract

Purpose: To prove the efficacy of Ursodeoxycholic acid Urdoksa as hepatoprotector in patients with cardiac fibrosis of the liver.Materials and Methods: We examined 30 patients before and after a month’s course of therapy with 500 mg per day.Results: All patients had statistically significant positive clinical dynamics in the form of reducing of the intensity of pain in the right upper quadrant, symptoms of dyspepsia, flatulence. Itching decreased or stopped in all patients, celebrating its pretreatment. There was not adverse events in any case. On biochemical parameters observed decrease ALT levels by an average of 32%, AST by 24%, total bilirubin level decreased by 54%.Summary: Our studies confirm the high clinical efficacy, good tolerability Urdoksa and quality of life in patients with cardiac fibrosis of the liver, which allows him to recommend this group of patients.

Keywords

• ursodeoxycholic acid
• urdoksa
• hepatoprotector
• cardiac fibrosis of the liver